Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases

Abstract : Dendritic cells are major contributors to inflammatory bone destruction in human through RANKL mediation and could represent a new therapeutic target. Bone-resorbing cells, osteoclasts (OCs), and antigen-presenting cells, dendritic cells (DCs), share several features. They are derived from a common hematopoietic precursor, exhibit phagocytic activities and their functions are dependent upon receptor activator of nuclear factor kB ligand (RANKL). Upon inflammatory conditions, DCs can transdifferentiate toward functional OCs in the presence of RANKL. It has then been assumed that the increase in proinflammatory cytokines could provide a supportive environment for this transdifferentiation. In this review, we emphasize the molecular mechanisms underlying the potential for DCs to give rise to resorbing OCs in the context of bone-destruction-associated diseases upon inflammatory conditions. Whether these mechanisms reveal new strategies for the discovery of therapeutic targets and drugs is discussed extensively.
Complete list of metadatas

Cited literature [76 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01845424
Contributor : Valérie Pecqueret <>
Submitted on : Friday, July 20, 2018 - 1:17:28 PM
Last modification on : Thursday, February 7, 2019 - 2:51:41 PM
Long-term archiving on: Sunday, October 21, 2018 - 7:20:59 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Olivier Lapérine, Claudine Blin-Wakkach, Jérôme Guicheux, Sarah Beck-Cormier, Philippe Lesclous. Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases. Drug Discovery Today, Elsevier, 2016, 21 (9), pp.1345 - 1354. ⟨10.1016/j.drudis.2016.04.022⟩. ⟨inserm-01845424⟩

Share

Metrics

Record views

381